Category: Metabolic surgery

Novo’s-$35B-Spending-Spree;-Mounjaro-Launches-in-Britain;-the-Obesity-Drug-Arms-Race;-Hip-Surgery-and-Semaglutide;-Kids-on-Wegovy

Novo’s $35B Spending Spree; Mounjaro Launches in Britain; the Obesity Drug-Arms Race; Hip Surgery and Semaglutide; Kids on Wegovy

February 18, 2024 No Comments

AT A GLANCE Reuters reports Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, plans to invest about $35 billion by 2030. Eli Lilly launches Mounjaro in Britain this week, for eligible private and NHS patients, from Reuters. Sy Mukherjee at Fast Company notes it is ‘…just the beginning for biopharma’s obesity-drug arms race.’ Patients on semaglutide undergoing hip replacement had lower readmission and

Read More »
Coca-Cola’s minimal impact of anti-obesity meds; counterfeit Ozempic and life-threatening seizures; first-graders in clinical obesity trials; $200B in obesity drug sales; and lower list prices.

Coca-Cola’s minimal impact of anti-obesity meds; counterfeit Ozempic and life-threatening seizures; first-graders in clinical obesity trials; $200B in obesity drug sales; and lower list prices.

October 29, 2023 No Comments

AT A GLANCE Coca-Cola CEO and chairman James Quincey said ‘…the company is currently seeing minimal impact from drugs like Ozempic and Wegovy…’, as per Eleanor Pringle at Fortune. The Austrian Federal Office for Safety in Health Care and the country’s criminal intelligence service reported ‘…Several people were hospitalized with life-threatening seizures and low blood sugar after taking counterfeit versions of the diabetes drug Ozempic.’ First graders with obesity,

Read More »
Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow - not shrink - along with rising GLP-1 adoption.

Demand for GLP-1s grow, some payors balking at the costs; bariatric and metabolic surgery anticipated to grow – not shrink – along with rising GLP-1 adoption.

September 1, 2023 No Comments

Hello everyone, I hope you are quite well on this beautiful weekend (at least, here in the US Northeast). Virtually everyone I know, including yours truly and family, are out & about enjoying it. In this edition of our twenty30 newsletter, we continue to see keen media attention on GLP-1s, helping facilitate public fascination and concurrent growing demand for them. This

Read More »
Categories
Archives
Scroll to Top
Skip to content